FDA Has Strong Words for Cancer Drug Developers
"In the end, patients may benefit from lower costs if Merck and Bristol-Myers face more rivals in the marketplace. Both Keytruda and Opdivo have a U.S. list price of about $150,000 per year.
If combinations of expensive therapies become the norm, drugmakers could theoretically keep prices lower by mixing their own treatments rather than seeking permission from a rival."
No comments:
Post a Comment